# US 2006/0154892 A1 · Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154892 A1
- Document ID: US20060154892A1
- Status: Published application
- Kind: A1
- Application number: 11/371,116
- Filed: 2006-03-08
- Published: 2006-07-13
- Earliest claimed: 1993-05-21
- Inventors: Franco Lori; Andrea Cara; Wen-Yi Gao; Robert Gallo
- Web page: https://patentgrep.com/patent/US20060154892A1

## CPC

- A61K 31/708: having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse- transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.

## Claims

### Claim 1

(canceled)

### Claim 2 (depends on 9)

The method of claim 9, wherein said virus is a retrovirus.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 9)

The method of claim 9, wherein said cells are in vitro.

### Claim 7 (depends on 9)

The method of claim 9, wherein said animal cells are mammalian cells.

### Claim 8 (depends on 9)

The method of claim 9 wherein said virus is the human immunodeficiency virus (HIV) and said cells are human cells.

### Claim 9

A method for inhibiting replication of reverse transcriptase dependent virus in animal cells, comprising the step of administering to said cells a synergistic combination of hydroxyurea and a nucleoside phosphate analog other than a thymidine or cytidine analog.

### Claim at position 8

10-11. (canceled)

### Claim 12

A method for inhibiting replication of reverse transcriptase dependent viruses in animal cells, comprising the step of administering to said cells a synergistic combination of hydroxyurea and a nucleoside phosphate analog other than a thymidine or cytidine analog, wherein the hydroxyurea depletes the intracellular pool of deoxyribonucleoside phosphate and wherein the nucleoside phosphate analog serves to inhibit replication of said virus by terminating DNA chain elongation.

### Claim at position 10

13-15. (canceled)

### Claim 16 (depends on 12)

The method of claim 12, wherein said second compound is selected from the group consisting of dideoxyinosine (ddI), 2′-fluoro-2′,3′-dideoxyadenosine (2′-F-dd-ara-A), 2′-fluoro-2′,3′-dideoxyinosine (2′-F-dd-ara-I), and 2′-fluoro-2′,3′-dideoxyguanosine (2′-F-dd-ara-G).

### Claim 17 (depends on 12)

The method of claim 12, wherein said nucleoside phosphate analog is a dideoxynucleoside.

### Claim 18 (depends on 17)

The method of claim 17, wherein said dideoxy nucleoside is a 2′-fluoro purine dideoxynucleoside.

### Claim 19 (depends on 17)

The method of claim 17, wherein said dideoxynucleoside is selected from the group consisting of dideoxyinosine (ddI), 2′-fluoro-2′,3′-dideoxyadenosine (2′-F-dd-ara-A), 2′-fluoro-2′,3′-dideoxyinosine (2′-F-dd-ara-I), and 2′-fluoro-2′,3′-dideoxyguanosine (2′-F-dd-ara-G).

### Claim 20

A method of producing incomplete viral DNA from a reverse transcriptase dependent virus in animal cells, comprising the step of administering to said cells a synergistic combination of hydroxyurea and a nucleoside phosphate analog other than a thymidine or cytidine analog, wherein the combination is administered in an amount effective to inhibit replication of said virus.
